ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa
Authors
Keywords
-
Journal
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-03-21
DOI
10.1093/jac/dkz149
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2
- (2019) Peera Hemarajata et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/tazobactam: place in therapy
- (2018) Daniele Roberto Giacobbe et al. Expert Review of Anti-Infective Therapy
- Past and Present Perspectives on β-Lactamases
- (2018) Karen Bush ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development
- (2018) Sherwin K. B. Sy et al. CLINICAL PHARMACOKINETICS
- Acquisition of Extended-Spectrum β-Lactamase GES-6 Leading to Resistance to Ceftolozane-Tazobactam Combination in Pseudomonas aeruginosa
- (2018) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Unravelling the genome of a Pseudomonas aeruginosa isolate belonging to the high-risk clone ST235 reveals an integrative conjugative element housing a blaGES-6 carbapenemase
- (2017) João Botelho et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16
- (2017) David M Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering
- (2017) Melissa D. Barnes et al. mBio
- Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
- (2016) David van Duin et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms
- (2016) Roopali Sharma et al. CLINICAL THERAPEUTICS
- In VitroPrediction of the Evolution of GES-1 β-Lactamase Hydrolytic Activity
- (2015) Séverine Bontron et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii : Mechanisms and epidemiology
- (2015) Anaïs Potron et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Impact of Renal Function on the Pharmacokinetics and Safety of Ceftolozane-Tazobactam
- (2014) Myra Wooley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases
- (2013) L Silvia Munoz-Price et al. LANCET INFECTIOUS DISEASES
- Integron Mobilization Unit as a Source of Mobility of Antibiotic Resistance Genes
- (2009) L. Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Minor extended-spectrum β-lactamases
- (2008) T. Naas et al. CLINICAL MICROBIOLOGY AND INFECTION
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started